S&P 500   3,297.52 (+0.50%)
DOW   27,200.22 (+0.19%)
QQQ   268.65 (+0.43%)
AAPL   111.28 (+1.09%)
MSFT   203.43 (+0.44%)
FB   249.22 (+0.43%)
GOOGL   1,443.44 (+0.93%)
AMZN   3,035.63 (+2.54%)
NVDA   488.30 (-2.47%)
TSLA   429.02 (-4.53%)
BABA   272.00 (-0.66%)
CGC   15.60 (-0.89%)
GE   6.38 (+0.47%)
MU   49.21 (+0.12%)
AMD   75.55 (-3.07%)
T   28.74 (+0.38%)
F   6.91 (+0.58%)
ACB   6.37 (+0.79%)
GILD   63.95 (-0.40%)
NFLX   485.00 (-0.48%)
DIS   126.07 (+0.53%)
BAC   24.25 (-0.90%)
BA   157.79 (+0.92%)
S&P 500   3,297.52 (+0.50%)
DOW   27,200.22 (+0.19%)
QQQ   268.65 (+0.43%)
AAPL   111.28 (+1.09%)
MSFT   203.43 (+0.44%)
FB   249.22 (+0.43%)
GOOGL   1,443.44 (+0.93%)
AMZN   3,035.63 (+2.54%)
NVDA   488.30 (-2.47%)
TSLA   429.02 (-4.53%)
BABA   272.00 (-0.66%)
CGC   15.60 (-0.89%)
GE   6.38 (+0.47%)
MU   49.21 (+0.12%)
AMD   75.55 (-3.07%)
T   28.74 (+0.38%)
F   6.91 (+0.58%)
ACB   6.37 (+0.79%)
GILD   63.95 (-0.40%)
NFLX   485.00 (-0.48%)
DIS   126.07 (+0.53%)
BAC   24.25 (-0.90%)
BA   157.79 (+0.92%)
S&P 500   3,297.52 (+0.50%)
DOW   27,200.22 (+0.19%)
QQQ   268.65 (+0.43%)
AAPL   111.28 (+1.09%)
MSFT   203.43 (+0.44%)
FB   249.22 (+0.43%)
GOOGL   1,443.44 (+0.93%)
AMZN   3,035.63 (+2.54%)
NVDA   488.30 (-2.47%)
TSLA   429.02 (-4.53%)
BABA   272.00 (-0.66%)
CGC   15.60 (-0.89%)
GE   6.38 (+0.47%)
MU   49.21 (+0.12%)
AMD   75.55 (-3.07%)
T   28.74 (+0.38%)
F   6.91 (+0.58%)
ACB   6.37 (+0.79%)
GILD   63.95 (-0.40%)
NFLX   485.00 (-0.48%)
DIS   126.07 (+0.53%)
BAC   24.25 (-0.90%)
BA   157.79 (+0.92%)
S&P 500   3,297.52 (+0.50%)
DOW   27,200.22 (+0.19%)
QQQ   268.65 (+0.43%)
AAPL   111.28 (+1.09%)
MSFT   203.43 (+0.44%)
FB   249.22 (+0.43%)
GOOGL   1,443.44 (+0.93%)
AMZN   3,035.63 (+2.54%)
NVDA   488.30 (-2.47%)
TSLA   429.02 (-4.53%)
BABA   272.00 (-0.66%)
CGC   15.60 (-0.89%)
GE   6.38 (+0.47%)
MU   49.21 (+0.12%)
AMD   75.55 (-3.07%)
T   28.74 (+0.38%)
F   6.91 (+0.58%)
ACB   6.37 (+0.79%)
GILD   63.95 (-0.40%)
NFLX   485.00 (-0.48%)
DIS   126.07 (+0.53%)
BAC   24.25 (-0.90%)
BA   157.79 (+0.92%)
Log in
NASDAQ:ICPT

Intercept Pharmaceuticals Stock Forecast, Price & News

$39.52
-0.69 (-1.72 %)
(As of 09/22/2020 10:22 AM ET)
Add
Compare
Today's Range
$39.13
Now: $39.52
$40.23
50-Day Range
$41.70
MA: $46.96
$53.44
52-Week Range
$39.46
Now: $39.52
$125.00
Volume2,921 shs
Average Volume758,813 shs
Market Capitalization$1.30 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.62
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults. The company is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis (NASH); and several other product candidates in various stages of clinical and preclinical development. Intercept Pharmaceuticals, Inc. has a license agreement with Sumitomo Dainippon Pharma Co. Ltd. for the research, development, and commercialization of OCA as a therapeutic for the treatment of PBC and NASH in Japan and China. The company was founded in 2002 and is headquartered in New York, New York.
Read More
Intercept Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.1Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.77 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ICPT
CUSIP45845P10
Phone646-747-1000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$252 million
Book Value$1.57 per share

Profitability

Net Income$-344,680,000.00
Net Margins-119.73%

Miscellaneous

Employees483
Market Cap$1.30 billion
Next Earnings Date11/3/2020 (Estimated)
OptionableOptionable
$39.52
-0.69 (-1.72 %)
(As of 09/22/2020 10:22 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ICPT News and Ratings via Email

Sign-up to receive the latest news and ratings for ICPT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Intercept Pharmaceuticals (NASDAQ:ICPT) Frequently Asked Questions

How has Intercept Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Intercept Pharmaceuticals' stock was trading at $77.60 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ICPT stock has decreased by 49.3% and is now trading at $39.35.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Intercept Pharmaceuticals?

24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intercept Pharmaceuticals in the last year. There are currently 17 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Intercept Pharmaceuticals
.

When is Intercept Pharmaceuticals' next earnings date?

Intercept Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Intercept Pharmaceuticals
.

How were Intercept Pharmaceuticals' earnings last quarter?

Intercept Pharmaceuticals Inc (NASDAQ:ICPT) issued its quarterly earnings results on Monday, August, 10th. The biopharmaceutical company reported ($1.92) earnings per share for the quarter, beating analysts' consensus estimates of ($2.94) by $1.02. The biopharmaceutical company had revenue of $77.60 million for the quarter, compared to analyst estimates of $72.45 million. Intercept Pharmaceuticals had a negative net margin of 119.73% and a negative return on equity of 1,973.10%. The firm's revenue was up 17.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($2.28) EPS.
View Intercept Pharmaceuticals' earnings history
.

What guidance has Intercept Pharmaceuticals issued on next quarter's earnings?

Intercept Pharmaceuticals issued an update on its FY 2020 Pre-Market earnings guidance on Monday, August, 10th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $300-320 million, compared to the consensus revenue estimate of $288.07 million.

What price target have analysts set for ICPT?

24 analysts have issued twelve-month target prices for Intercept Pharmaceuticals' stock. Their forecasts range from $46.00 to $140.00. On average, they anticipate Intercept Pharmaceuticals' share price to reach $75.61 in the next twelve months. This suggests a possible upside of 92.1% from the stock's current price.
View analysts' price targets for Intercept Pharmaceuticals
.

Who are some of Intercept Pharmaceuticals' key competitors?

What other stocks do shareholders of Intercept Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intercept Pharmaceuticals investors own include Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Tesla (TSLA), Netflix (NFLX), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Ionis Pharmaceuticals (IONS), Regeneron Pharmaceuticals (REGN) and Biogen (biib).

Who are Intercept Pharmaceuticals' key executives?

Intercept Pharmaceuticals' management team includes the following people:
  • Dr. Mark Pruzanski, Founder, CEO, Pres & Director (Age 51)
  • Mr. Sandip S. Kapadia, CFO, Treasurer & Principal Accounting Officer (Age 49)
  • Mr. Jerome B. Durso, Chief Operating Officer (Age 51)
  • Mr. Ryan T. Sullivan, Gen. Counsel & Sec. (Age 43)
  • Dr. Gail Cawkwell, Sr. VP of Medical Affairs, Safety & Pharmacovigilance (Age 57)

What is Intercept Pharmaceuticals' stock symbol?

Intercept Pharmaceuticals trades on the NASDAQ under the ticker symbol "ICPT."

Who are Intercept Pharmaceuticals' major shareholders?

Intercept Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (7.54%), First Trust Advisors LP (2.45%), Macquarie Group Ltd. (2.33%), Bellevue Group AG (2.14%), Two Sigma Advisers LP (1.56%) and Goldman Sachs Group Inc. (1.27%). Company insiders that own Intercept Pharmaceuticals stock include Christian Weyer, David A Ford, David Shapiro, Gail Cawkwell, Jason Campagna, Lisa Bright, Luca Benatti, Mark Pruzanski, Paolo Fundaro, Ryan T Sullivan, SPA Genextra and Srinivas Akkaraju.
View institutional ownership trends for Intercept Pharmaceuticals
.

Which institutional investors are selling Intercept Pharmaceuticals stock?

ICPT stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Advisers LP, Cubist Systematic Strategies LLC, Alps Advisors Inc., TD Asset Management Inc., Bellevue Group AG, Bank of Montreal Can, Pinnacle Associates Ltd., and Jacobi Capital Management LLC. Company insiders that have sold Intercept Pharmaceuticals company stock in the last year include Christian Weyer, David A Ford, Gail Cawkwell, Jason Campagna, Lisa Bright, Mark Pruzanski, Paolo Fundaro, Ryan T Sullivan, and SPA Genextra.
View insider buying and selling activity for Intercept Pharmaceuticals
.

Which institutional investors are buying Intercept Pharmaceuticals stock?

ICPT stock was bought by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Goldman Sachs Group Inc., Vanguard Group Inc., Man Group plc, Macquarie Group Ltd., Tekla Capital Management LLC, Charles Schwab Investment Management Inc., and Principal Financial Group Inc.. Company insiders that have bought Intercept Pharmaceuticals stock in the last two years include Luca Benatti, and Srinivas Akkaraju.
View insider buying and selling activity for Intercept Pharmaceuticals
.

How do I buy shares of Intercept Pharmaceuticals?

Shares of ICPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Intercept Pharmaceuticals' stock price today?

One share of ICPT stock can currently be purchased for approximately $39.35.

How big of a company is Intercept Pharmaceuticals?

Intercept Pharmaceuticals has a market capitalization of $1.30 billion and generates $252 million in revenue each year. The biopharmaceutical company earns $-344,680,000.00 in net income (profit) each year or ($10.89) on an earnings per share basis. Intercept Pharmaceuticals employs 483 workers across the globe.

What is Intercept Pharmaceuticals' official website?

The official website for Intercept Pharmaceuticals is www.interceptpharma.com.

How can I contact Intercept Pharmaceuticals?

Intercept Pharmaceuticals' mailing address is 10 Hudson Yards 37th FL, New York NY, 10001. The biopharmaceutical company can be reached via phone at 646-747-1000 or via email at [email protected]

This page was last updated on 9/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.